Royal Bank of Canada’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Royal Bank of Canada’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-109	Closed	–	–	7816
2023 Q3	$0	Hold	109	–	–	﹤0.01%	7842
2023 Q2	$0	Buy	+109	New	+$165	﹤0.01%	7857
2022 Q4	–	Sell	-75	Closed	–	–	7959
2022 Q3	$0	Buy	+75	New	+$574	﹤0.01%	8060
2022 Q2	–	Sell	-426	Closed	-$3K	–	7900
2022 Q1	$3K	Sell	426 -1,005	-70%	-$7.6K	﹤0.01%	7424
2021 Q4	$13K	Buy	1,431 +725	+103%	+$7.24K	﹤0.01%	6985
2021 Q3	$8K	Buy	706 +336	+91%	+$4.88K	﹤0.01%	7042
2021 Q2	$3K	Buy	+370	New	+$4.42K	﹤0.01%	7203

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Royal Bank of Canada's IMPL Position: Q4 2023 in Review

Royal Bank of Canada sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 109 shares.

Royal Bank of Canada first reported a position in IMPL in Q2 2021 and held it in 7 quarters. The position peaked at $13K in Q4 2021. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

Royal Bank of Canada reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Royal Bank of Canada sold 109 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023.
Royal Bank of Canada first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 7 quarters.
Royal Bank of Canada's Impel Pharmaceuticals Inc. Common Stock position peaked at $13K in Q4 2021.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Royal Bank of Canada's 13F filing for Q4 2023, filed 14 Feb 2024.